News

Combining certain medications or psychotherapy with transcranial magnetic stimulation (TMS) or transcranial direct current stimulation (tDCS) may decrease symptoms of major depressive disorder (MDD), though some limitations still exist, according to a review published in the Harvard Review of Psychiatry. 

Patients with major depressive disorder (MDD) and anhedonia (MDD-ANH) may have more severe depressive symptoms than patients with MDD and no/low anhedonia (other-MDD) as well as lower percentages of remission in the year following initial assessment, according to results from a retrospective cohort study presented via poster.

The prevalence of major depressive disorder (MDD) at a major health system was 3 times higher in female patients with Huntington disease (HD) than in male patients, according to a poster presentation on May 5, 2024, at the American Psychiatric Association Annual Meeting in New York, New York.

The US Food and Drug Administration (FDA) approved Rejoyn, the first prescription digital therapeutic for the treatment of major depressive disorder (MDD) symptoms.

Multilocus sequential repetitive transcranial magnetic stimulation (rTMS) reduced tinnitus symptom severity in both patients with and without comorbid major depressive disorder (MDD) in a recent open-label treatment study published in Neuromodulation.